副甲状腺疾患市場：タイプ別、疾患タイプ別、投与経路別、年齢層別、性別、エンドユーザー別、流通チャネル別、地域別

副甲状腺疾患の世界市場は、2025年に111億米ドルと推定され、2032年には139億3,000万米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は3.3％で成長すると予測されています。

世界の副甲状腺疾患市場は、副甲状腺疾患の有病率の増加、診断技術の進歩、新規治療オプションの開発などを背景に、近年著しい成長を遂げています。副甲状腺疾患には、副甲状腺機能亢進症や副甲状腺機能低下症が含まれ、副甲状腺の機能異常によって体内のカルシウムとリン酸のバランスが崩れることが特徴です。これらの疾患は、骨の健康、心血管系の機能、生活の質全体に深刻な影響を及ぼす可能性があります。副甲状腺疾患に対する認識が高まり、先進的な治療法が利用できるようになったことから、世界の副甲状腺疾患市場は予測期間中に大幅な成長を遂げると予想されます。

市場力学：

世界の副甲状腺疾患市場は、副甲状腺疾患、特に閉経後の女性に多い原発性副甲状腺機能亢進症の有病率の増加など、いくつかの要因によって牽引されています。さらに、副甲状腺疾患に罹患しやすい老年人口が増加していることも、市場の成長に拍車をかけると予想されます。改良された画像診断モダリティや遺伝子検査などの診断技術の進歩は、副甲状腺疾患の早期発見と正確な診断を可能にし、市場の成長をさらに促進しています。さらに、標的治療や低侵襲外科手術などの新しい治療法の開発により、治療の選択肢が広がり、患者の転帰が改善されています。しかし、治療費が高額であること、特定の地域では副甲状腺疾患に対する認識が限定的であること、一部の治療法に伴う潜在的な副作用などの要因により、市場の成長が抑制される可能性があります。このような抑制要因にもかかわらず、研究開発活動への注目の高まり、業界各社と学術機関との協力関係、副甲状腺疾患分野における個別化医療アプローチの出現などにより、市場には大きな成長機会がもたらされています。

本調査の主な特徴

• 本レポートでは、世界の副甲状腺疾患市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（10億米ドル）および複合年間成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいて、世界の副甲状腺疾患市場における主要企業プロファイルを掲載しています。
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• この調査レポートは、投資家、サプライヤー、製品メーカー、販売業者、新規参入者、財務アナリストなど、この業界のさまざまな利害関係者を対象としています。
• 利害関係者は、世界の副甲状腺疾患市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

  目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー

第3章 市場力学、規制、動向分析

• 市場力学
• 促進要因
• 抑制要因
• 機会
• 影響分析
• 主な発展
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 合併と買収のシナリオ
• 業界動向

第4章 世界の副甲状腺疾患市場、タイプ別、2020年～2032年

• 薬物クラス
• 副甲状腺ホルモン（PTH）類似体
• ビスホスホネート
• カルシウム刺激薬
• ビタミンD類似体
• リン酸結合剤
• 診断方法
• 血液検査
• 画像技術
• 尿検査

第5章 世界の副甲状腺疾患市場、疾患タイプ別、2020年～2032年

• 原発性副甲状腺機能亢進症
• 二次性副甲状腺機能亢進症
• 第三次性副甲状腺機能亢進症
• 副甲状腺機能低下症

第6章 世界の副甲状腺疾患市場、投与経路別、2020年～2032年

• 経口
• 非経口

第7章 世界の副甲状腺疾患市場、年齢グループ別、2020年～2032年

• 小児
• 成人
• 高齢者

第8章 世界の副甲状腺疾患市場、性別、2020年～2032年

• 男
• 女性

第9章 世界の副甲状腺疾患市場、エンドユーザー別、2020年～2032年

• 病院
• 専門クリニック
• 外来センター
• 研究機関
• 診断センター
• 在宅ヘルスケア

第10章 世界の副甲状腺疾患市場、流通チャネル別、2020年～2032年

• 病院薬局
• 小売薬局
• オンライン薬局

第11章 世界の副甲状腺疾患市場、地域別、2020年～2032年

• 北米
  • 米国
  • カナダ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • メキシコ
  • その他ラテンアメリカ
• 欧州
  • ドイツ
  • 英国
  • スペイン
  • フランス
  • イタリア
  • ロシア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • ASEAN
  • その他アジア太平洋地域
• 中東
  • GCC諸国
  • イスラエル
  • その他中東
• アフリカ
  • 南アフリカ
  • 北アフリカ
  • 中央アフリカ

第12章 競合情勢

• Amgen Inc.
• Eli Lilly and Company
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Regeneron Pharmaceuticals, Inc.
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• Sandoz（a Novartis division）
• Otsuka Pharmaceutical Co., Ltd.

第13章 アナリストの推奨事項

• 機会
• アナリストの見解
• Coherent Opportunity Map

第14章 参考文献と調査手法

• 参考文献
• 調査手法
• 出版社について

Global Parathyroid Disorders Market is estimated to be valued at USD 11.10 Bn in 2025 and is expected to reach USD 13.93 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.3% from 2025 to 2032.

The global parathyroid disorders market has witnessed significant growth in recent years, driven by the increasing prevalence of parathyroid disorders, advancements in diagnostic techniques, and the development of novel treatment options. Parathyroid disorders, which include hyperparathyroidism and hypoparathyroidism, are characterized by abnormal functioning of the parathyroid glands, leading to imbalances in calcium and phosphate levels in the body. These disorders can have severe consequences on bone health, cardiovascular function, and overall quality of life. With the rising awareness about parathyroid disorders and the availability of advanced treatment modalities, the global parathyroid disorders market is expected to experience substantial growth during the forecast period.

Market Dynamics:

The global parathyroid disorders market is driven by several factors, including the increasing prevalence of parathyroid disorders, particularly primary hyperparathyroidism, which is more common in postmenopausal women. Additionally, the growing geriatric population, which is more susceptible to parathyroid disorders, is expected to fuel market growth. Advancements in diagnostic techniques, such as improved imaging modalities and genetic testing, have enabled early detection and accurate diagnosis of parathyroid disorders, further driving market growth. Moreover, the development of novel treatment options, including targeted therapies and minimally invasive surgical procedures, has expanded the treatment landscape and improved patient outcomes. However, the market growth may be restrained by factors such as the high cost of treatments, limited awareness about parathyroid disorders in certain regions, and the potential side effects associated with some treatment options. Despite these restraints, the market presents significant opportunities for growth, driven by the increasing focus on research and development activities, collaborations between industry players and academic institutions, and the emergence of personalized medicine approaches in the field of parathyroid disorders.

Key Features of the Study:

• This report provides in-depth analysis of the global parathyroid disorders market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global parathyroid disorders market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Regeneron Pharmaceuticals, Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Sandoz (a Novartis division), and Otsuka Pharmaceutical Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global parathyroid disorders market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global parathyroid disorders market

Market Segmentation

• Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Drug Class
  • Parathyroid Hormone (PTH) Analogues
  • Bisphosphonates
  • Calcimimetics
  • Vitamin D Analogues
  • Phosphate Binders
  • Diagnostic Method
  • Blood Tests
  • Imaging Techniques
  • Urine Tests
• Disorder Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Primary Hyperparathyroidism
  • Secondary Hyperparathyroidism
  • Tertiary Hyperparathyroidism
  • Hypoparathyroidism
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Parenteral
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Pediatric
  • Adult
  • Geriatric
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Outpatient Centers
  • Research Institutes
  • Diagnostic Centers
  • Home Healthcare
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Amgen Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sandoz (a Novartis division)
  • Otsuka Pharmaceutical Co., Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Parathyroid Disorders Market, By Type
  • Global Parathyroid Disorders Market, By Disorder Type
  • Global Parathyroid Disorders Market, By Route of Administration
  • Global Parathyroid Disorders Market, By Age Group
  • Global Parathyroid Disorders Market, By Gender
  • Global Parathyroid Disorders Market, By End User
  • Global Parathyroid Disorders Market, By Distribution Channel
  • Global Parathyroid Disorders Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Parathyroid Disorders Market, By Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Drug Class
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parathyroid Hormone (PTH) Analogues
• Bisphosphonates
• Calcimimetics
• Vitamin D Analogues
• Phosphate Binders
• Diagnostic Method
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Blood Tests
• Imaging Techniques
• Urine Tests

5. Global Parathyroid Disorders Market, By Disorder Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Primary Hyperparathyroidism
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Secondary Hyperparathyroidism
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Tertiary Hyperparathyroidism
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hypoparathyroidism
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Parathyroid Disorders Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Parathyroid Disorders Market, By Age Group, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Adult
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Parathyroid Disorders Market, By Gender, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Male
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Female
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Parathyroid Disorders Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Outpatient Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Research Institutes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Diagnostic Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Home Healthcare
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Parathyroid Disorders Market, By Distribution Channel, 202-02032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Parathyroid Disorders Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Disorder Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

12. Competitive Landscape

• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regeneron Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Astellas Pharma Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sandoz (a Novartis division)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Otsuka Pharmaceutical Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

13. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

14. References and Research Methodology

• References
• Research Methodology
• About us